2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Head & Neck
1
Conditions
Breast Neoplasms
9
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Diseases
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Surveys and Questionnaires
23
Radiotherapy
22
Letrozole
22
Doxorubicin
21
Megestrol Acetate
20
olaparib
19
lenvatinib
19
Taxes
17
Specimen Handling
17
Docetaxel
17
Nivolumab
16
Magnetic Resonance Spectroscopy
16
dostarlimab
15
Metformin
15
Blood Specimen Collection
14
Observation
13
Gemcitabine
13
Biopsy
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
temsirolimus
10
abemaciclib
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Imlunestrant
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled